Pretreatment and posttreatment parameters in major anemia responders with MMM
. | . | . | . | . | . | Hgb, g/L . | . | WBC, × 109/L . | . | Platelet count, × 109/L . | . | Spleen, cm . | . | LDH, U/L* . | . | Cytogenetics . | . | Angiogenesis grade . | . | JAK2V617F . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt. no. . | Age, y/sex . | Diagnosis . | Treatment center . | Previous treatment . | Disease duration, mo . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | ||||||||
| 1 | 75/M | PPMM | Mayo | None | 1 | 94 | 156 | 6.7 | 4.9 | 831 | 101 | 8 | 0 | 414 | 118 | AA del(5)(q13q33) | NN | 2 | 1 | Hetero | Hetero | ||||||||
| 2 | 66/M | AMM | Mayo | Epo | 4 | Tx† | 140 | 6.1 | 2.3 | 212 | 239 | NP | NP | 536 | 184 | NN | NN | 2 | 1 | Hetero | Hetero | ||||||||
| 3 | 56/F | PTMM | Mayo | HU; anagrelide | 2 | 83 | 136 | 66.2 | 6.6 | 349 | 896 | NP | NP | 829 | 168 | NN | NN | 3 | 3 | WT | ND | ||||||||
| 4 | 78/F | PPMM | Mayo | HU; pred; 2-CdA; Zamestra | 27 | Tx | 191 | 16.1 | 3.4 | 430 | 218 | 9 | 4 | 1058 | 178 | AA der(1;18)(q10;q10) | AA | 2 | 2 | Homo | Homo | ||||||||
| 5 | 48/F | AMM | MDACC | IFN; thalidomide | 47 | 85 | 138 | 6.2 | 3.2 | 35 | 86 | 10 | 2 | 562 | 244 | AA Trisomy 9 | AA Trisomy 9 | ND | ND | Hetero | Hetero | ||||||||
| 6 | 64/F | AMM | MDACC | Epo; thalidomide; Gleevec | 39 | 96 | 120 | 2.9 | 2.4 | 233 | 152 | 3 | 0 | 470 | 333 | NN | ND | ND | ND | WT | ND | ||||||||
| 7 | 51/F | AMM | MDACC | None | 0 | Tx | 124 | 5.4 | 2.9 | 275 | 124 | NP | NP | 581 | 431 | NN | NN | ND | ND | WT | ND | ||||||||
| 8 | 58/M | AMM | MDACC | None | 1 | 94 | 125 | 11.2 | 20.6 | 43 | 30 | NP | NP | 2779 | 2369 | NN | ND | ND | ND | WT | ND | ||||||||
. | . | . | . | . | . | Hgb, g/L . | . | WBC, × 109/L . | . | Platelet count, × 109/L . | . | Spleen, cm . | . | LDH, U/L* . | . | Cytogenetics . | . | Angiogenesis grade . | . | JAK2V617F . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt. no. . | Age, y/sex . | Diagnosis . | Treatment center . | Previous treatment . | Disease duration, mo . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | Pre . | Post . | ||||||||
| 1 | 75/M | PPMM | Mayo | None | 1 | 94 | 156 | 6.7 | 4.9 | 831 | 101 | 8 | 0 | 414 | 118 | AA del(5)(q13q33) | NN | 2 | 1 | Hetero | Hetero | ||||||||
| 2 | 66/M | AMM | Mayo | Epo | 4 | Tx† | 140 | 6.1 | 2.3 | 212 | 239 | NP | NP | 536 | 184 | NN | NN | 2 | 1 | Hetero | Hetero | ||||||||
| 3 | 56/F | PTMM | Mayo | HU; anagrelide | 2 | 83 | 136 | 66.2 | 6.6 | 349 | 896 | NP | NP | 829 | 168 | NN | NN | 3 | 3 | WT | ND | ||||||||
| 4 | 78/F | PPMM | Mayo | HU; pred; 2-CdA; Zamestra | 27 | Tx | 191 | 16.1 | 3.4 | 430 | 218 | 9 | 4 | 1058 | 178 | AA der(1;18)(q10;q10) | AA | 2 | 2 | Homo | Homo | ||||||||
| 5 | 48/F | AMM | MDACC | IFN; thalidomide | 47 | 85 | 138 | 6.2 | 3.2 | 35 | 86 | 10 | 2 | 562 | 244 | AA Trisomy 9 | AA Trisomy 9 | ND | ND | Hetero | Hetero | ||||||||
| 6 | 64/F | AMM | MDACC | Epo; thalidomide; Gleevec | 39 | 96 | 120 | 2.9 | 2.4 | 233 | 152 | 3 | 0 | 470 | 333 | NN | ND | ND | ND | WT | ND | ||||||||
| 7 | 51/F | AMM | MDACC | None | 0 | Tx | 124 | 5.4 | 2.9 | 275 | 124 | NP | NP | 581 | 431 | NN | NN | ND | ND | WT | ND | ||||||||
| 8 | 58/M | AMM | MDACC | None | 1 | 94 | 125 | 11.2 | 20.6 | 43 | 30 | NP | NP | 2779 | 2369 | NN | ND | ND | ND | WT | ND | ||||||||
Hgb indicates hemoglobin level; WBC, white blood cell count; NP, not palpable; ND, not done; hetero, appears heterozygous by sequencing; homo, appears homozygous by sequencing; wild-type, appears wild type by sequencing; NN, all metaphases normal; AA, all metaphases abnormal; Epo, erythropoietin; HU, hydroxyurea; Pred, prednisone; 2-CdA, cladribine; Mayo, Mayo Clinic, Rochester, MN; MDACC, M. D. Anderson Cancer Center, Houston, TX.
Reference range for LDH level: 122-222 U/L for the Mayo Clinic and 313-618 U/L for MDACC.
Tx indicates red blood cell transfusion dependent. Hemoglobin levels that triggered transfusion were lower than 8 g/dL in all instances.